ESMO 2025 Breast Cancer Data May Redefine Treatment Standards Across Patient Subgroups

The ESMO 2025 Congress unveiled significant advancements in breast cancer treatment across various subtypes. Key data showed Enhertu (T-DXd) improving pathologic complete response in HER2-positive early breast cancer and invasive disease-free survival in primary HER2-positive disease. Datroway (Dato-DXd) and Trodelvy (sacituzumab govitecan) demonstrated substantial progression-free and overall survival benefits in metastatic triple-negative breast cancer. Furthermore, camizestrant, giredestrant, and gedatolisib-based regimens reported enhanced progression-free survival and patient-reported outcomes in hormone receptor-positive, HER2-negative advanced breast cancer, collectively signaling a potential redefinition of treatment standards.

Analysis

The ESMO 2025 Congress presented highly positive clinical trial data across various breast cancer subtypes, signaling a potential redefinition of treatment standards. Enhertu (T-DXd) demonstrated significant efficacy in HER2-positive early and primary breast cancer, achieving a 67.3% pathologic complete response rate in DESTINY-Breast11 and a 53% reduction in invasive disease recurrence risk in DESTINY-Breast05. This was observed despite a notable interstitial lung disease (ILD) rate of 9.6% for T-DXd in DESTINY-Breast05.

Further advancements were seen in triple-negative breast cancer (TNBC) with Datroway (Dato-DXd) and Trodelvy (sacituzumab govitecan). Dato-DXd significantly improved median progression-free survival (PFS) to 10.8 months and overall survival (OS) to 23.7 months in metastatic TNBC, while sacituzumab govitecan extended median PFS to 9.7 months and duration of response to 12.2 months in previously untreated metastatic TNBC. Both drugs significantly outperformed chemotherapy, with Dato-DXd achieving an ORR of 62.5% versus 29.3% for chemotherapy.

In hormone receptor-positive, HER2-negative advanced breast cancer, camizestrant, giredestrant, and gedatolisib-based regimens reported strong positive outcomes. Camizestrant improved PFS to 16.0 months and delayed quality of life deterioration to 21.0 months, while giredestrant plus everolimus reduced progression risk by 62%. Gedatolisib-based triplets achieved a median PFS of 9.3 months, collectively offering new effective options with manageable safety profiles. These results, coupled with a "strongly positive" sentiment and high market impact score, underscore substantial therapeutic progress.

Key Decisions for Investors

• Investors should evaluate the long-term market penetration potential for Enhertu, Datroway, and Trodelvy given their strong efficacy data in HER2-positive and TNBC, Monitor the competitive landscape and potential label expansions for camizestrant, giredestrant, and gedatolisib, which are poised to redefine treatment for HR+/HER2- advanced breast cancer, Assess the balance between efficacy and safety profiles, such as Enhertu's 9.6% ILD risk, as these factors will influence physician adoption and market share.